TBC1D3G: A Potential Drug Target and Biomarker (G101060321)

Target Name: TBC1D3G

NCBI ID: G101060321

TBC1D3G

TBC1D3G: A Potential Drug Target and Biomarker

Tumor suppressor genes (TSGs) are important regulators of cancer growth and progression. TBC1D3G, a gene encoding a protein known as TBC1D3, has been identified as a potential drug target in various types of cancer. This gene has been shown to play a crucial role in the development and progression of various cancers, including breast, ovarian, and colorectal cancer.

The TBC1D3 gene is part of the TBC1 family, which is known for its role in regulating cell growth and differentiation. The TBC1D3 gene encodes a protein that is composed of 214 amino acids and has been shown to interact with various proteins, including TBC1D2, a gene also known as CDK4 kinase.

Studies have shown that TBC1D3G is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. It has also been shown to be involved in the development of various types of cancer, including neurobladder cancer and leukemia.

One of the key challenges in studying TBC1D3G is its expression and function in cancer. However, research has shown that TBC1D3G is involved in various signaling pathways that are important for cancer growth and progression.

For example, studies have shown that TBC1D3G is involved in the PI3K/Akt signaling pathway, a pathway that is important for cancer cell survival and growth. This pathway is known to be altered in various types of cancer, including breast, ovarian, and colorectal cancer.

Additionally, TBC1D3G has been shown to be involved in the NF-kappa-B signaling pathway, a pathway that is important for cancer cell growth and survival. This pathway is known to be altered in various types of cancer, including breast, ovarian, and colorectal cancer.

Another study has shown that TBC1D3G is involved in the TGF-β signaling pathway, a pathway that is important for cancer cell growth and development. This pathway is known to be altered in various types of cancer, including breast, ovarian, and colorectal cancer.

In conclusion, TBC1D3G is a potential drug target and biomarker for various types of cancer. Its involvement in various signaling pathways that are important for cancer growth and progression makes it an attractive target for drug development. Further research is needed to fully understand the role of TBC1D3G in cancer and to develop effective treatments.

Protein Name: TBC1 Domain Family Member 3G

Functions: Acts as a GTPase activating protein for RAB5. Does not act on RAB4 or RAB11 (By similarity)

The "TBC1D3G Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBC1D3G comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets